<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Trandolapril</id>
	<title>Trandolapril - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Trandolapril"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Trandolapril&amp;action=history"/>
	<updated>2026-04-26T21:05:52Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Trandolapril&amp;diff=4968489&amp;oldid=prev</id>
		<title>Prab at 18:57, 17 September 2023</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Trandolapril&amp;diff=4968489&amp;oldid=prev"/>
		<updated>2023-09-17T18:57:27Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{intro}}&lt;br /&gt;
[[File:Trandolapril structure.svg|Trandolapril structure|thumb]]&lt;br /&gt;
Trandolapril is an oral angiotensin-converting enzyme (ACE) inhibitor used in the therapy of hypertension and heart failure.  &lt;br /&gt;
{{livtox}}&lt;br /&gt;
Trandolapril is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury.&lt;br /&gt;
{{moa}}&lt;br /&gt;
Trandolapril (tran dol&amp;#039; a pril) is an ACE inhibitor which is approved for use alone and in combination with other agents in the therapy of hypertension and congestive heart failure.  Like other ACE inhibitors, trandolapril inhibits the conversion of angiotensin I, a relatively inactive molecule, to angiotensin II which is the major mediator of vasoconstriction and volume expansion induced by the renin-angiotensin system.  Other host enzymes besides that which converts angiotensin I to II may be inhibited as well, which may account for some of the side effects of the ACE inhibitors.  &lt;br /&gt;
{{fda}}&lt;br /&gt;
Trandolapril was approved for use in the United States in 1996 and is available in 1, 2 and 4 mg tablets in generic forms and under the trade name Mavik.  &lt;br /&gt;
{{dose}}&lt;br /&gt;
The typical daily dose in adults is 2 to 4 mg in one or two divided doses which is administered long term.  Trandolapril is also available in fixed dose combinations with verapamil (Tarka and generics).  &lt;br /&gt;
{{se}}&lt;br /&gt;
Common side effects include dizziness, fatigue, headache, cough, gastrointestinal upset and skin rash.&lt;br /&gt;
{{coststubd}}&lt;br /&gt;
{{ACE inhibitors}}&lt;br /&gt;
[[Category:ACE inhibitors]]&lt;br /&gt;
[[Category:Enantiopure drugs]]&lt;br /&gt;
[[Category:Prodrugs]]&lt;br /&gt;
[[Category:Indoles]]&lt;br /&gt;
[[Category:Ethyl esters]]&lt;br /&gt;
[[Category:Amides]]&lt;br /&gt;
[[Category:Carboxylic acids]]&lt;br /&gt;
{{Angiotensin receptor modulators}}&lt;br /&gt;
[[Category:Angiotensin II receptor antagonists]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>